103392-84-3

Basic information

• Product Name: 2-tert-Butyl-5-nitro-phenylamine
• Synonyms: 2-tert-Butyl-5-nitro-phenylamine;2-Tert-Butyl-5-Nitroaniline(WX602011)
• CAS NO: 103392-84-3
• Molecular Formula: C₁₀H₁₄N₂O₂
• Molecular Weight: 194.23036
• Mol File: 103392-84-3.mol

Chemical Properties

• Boiling Point: 334.7±30.0 °C(Predicted)
• Appearance: /
• Density: 1.140±0.06 g/cm3(Predicted)
• PKA: 1.69±0.10(Predicted)
• CAS DataBase Reference: 2-tert-Butyl-5-nitro-phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-tert-Butyl-5-nitro-phenylamine(103392-84-3)
• EPA Substance Registry System: 2-tert-Butyl-5-nitro-phenylamine(103392-84-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-37/39
• Hazardous Substances Data: 103392-84-3(Hazardous Substances Data)

Upstream product

• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 7402-70-2 N-(2-tert-butylphenyl)acetamide 
• 342045-15-2 N-(2-tert-butyl-5-nitro-phenyl)-acetamide 

Downstream Products

• 442847-11-2 2-(tert-butyl)-5-nitrophenol 
• 618446-15-4 2-bromo-N-(2-tert-butyl-5-nitro-phenyl)-acetamide 
• 52756-38-4 1-(tert-butyl)-2-chloro-4-nitrobenzene 
• 489-18-9 1-(tert-butyl)-2-fluoro-4-nitrobenzene 
• 342045-15-2 N-(2-tert-butyl-5-nitro-phenyl)-acetamide 
• 873056-35-0 2-tert-butyl-5-nitrobenzene-1-sulfonyl chloride 
• 850040-16-3 1-t-butyl-2-fluoro-4-nitrobenzene 
• 873056-36-1 2-tert-butyl-5-nitrobenzene-1-sulfonamide 
• 873056-37-2 2-tert-butyl-5-aminobenzene-1-sulfonamide 
• 35291-89-5 4-tert-butyl-3-methoxyaniline 
• 873055-35-7 2-tert-butyl-5-aminophenol 
• 35292-23-0 1-tert-butyl-2-methoxy-4-nitrobenzene 
• 873052-82-5 N-(4-tert-butyl-3-sulfamoylphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 1236059-67-8 N-(4-tert-butyl-3-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 

Relevant articles and documents

TEAD INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809

The 1,2,3-triazole has been successfully utilized as an amide bioisostere in multiple therapeutic contexts. Based on this precedent, triazole analogues derived from VX-809 and VX-770, prominent amide-containing modulators of the cystic fibrosis transmembrane conductance regulator (CFTR), were synthesized and evaluated for CFTR modulation. Triazole 11, derived from VX-809, displayed markedly reduced efficacy in F508del-CFTR correction in cellular TECC assays in comparison to VX-809. Surprisingly, triazole analogues derived from potentiator VX-770 displayed no potentiation of F508del, G551D, or WT-CFTR in cellular Ussing chamber assays. However, patch clamp analysis revealed that triazole 60 potentiates WT-CFTR similarly to VX-770. The efficacy of 60 in the cell-free patch clamp experiment suggests that the loss of activity in the cellular assay could be due to the inability of VX-770 triazole derivatives to reach the CFTR binding site. Moreover, in addition to the negative impact on biological activity, triazoles in both structural classes displayed decreased metabolic stability in human microsomes relative to the analogous amides. In contrast to the many studies that demonstrate the advantages of using the 1,2,3-triazole, these findings highlight the negative impacts that can arise from replacement of the amide with the triazole and suggest that caution is warranted when considering use of the 1,2,3-triazole as an amide bioisostere.

Palladium-Catalyzed Intermolecular [4+1] Spiroannulation by C(sp3)?H Activation and Naphthol Dearomatization

A novel palladium-catalyzed [4+1] spiroannulation was developed by using a C(sp3)?H activation/naphthol dearomatization approach. This bimolecular domino reaction of two aryl halides was realized through a sequence of cyclometallation-facilitat

Heterocyclic compound

The present invention relates to compound (I) or a salt thereof which has a ROR γ t inhibitory action. wherein each symbol is as defined in the specification.

AMIDE COMPOUND

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

Catalytic C(sp3)?H Arylation of Free Primary Amines with an exo Directing Group Generated In Situ

Herein, we report the palladium-catalyzed direct arylation of unactivated aliphatic C?H bonds in free primary amines. This method takes advantage of an exo-imine-type directing group (DG) that can be generated and removed in situ. A range of unprotected aliphatic amines are suitable substrates, undergoing site-selective arylation at the γ-position. Methyl as well as cyclic and acyclic methylene groups can be activated. Furthermore, when aniline-derived substrates were used, preliminary success with δ-C?H arylation was achieved. The feasibility of using the DG component in a catalytic fashion was also demonstrated.

Oxidative fluorination of N-arylsulfonamides

We report a late stage oxidative nucleophilic fluorination of N-arylsulfonamides, a class of compounds so far not considered as precursors to 4-fluorophenyl sulfonamides. By installing a para-positioned tert-butyl substituent on the aniline, oxidative fluorination takes place regioselectively in the presence of HF·pyridine and PIDA. This methodology has been shown to give good yields for a variety of ortho- and meta-functionalised N-arylsulfonamides and has been adapted for radiofluorination to give 4-[18F]fluorophenyl sulfonamides under carrier added conditions.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator

Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.